GOSS vs. MOR, RARE, CGON, OGN, IMVT, KNSA, GMTX, MLYS, BHC, and IBRX
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include MorphoSys (MOR), Ultragenyx Pharmaceutical (RARE), CG Oncology (CGON), Organon & Co. (OGN), Immunovant (IMVT), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), Mineralys Therapeutics (MLYS), Bausch Health Cos (BHC), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs. Its Competitors
Gossamer Bio (NASDAQ:GOSS) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.
Gossamer Bio has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
In the previous week, Gossamer Bio had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Gossamer Bio and 0 mentions for MorphoSys. Gossamer Bio's average media sentiment score of 0.55 beat MorphoSys' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 6.7% of Gossamer Bio shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Gossamer Bio currently has a consensus target price of $8.50, suggesting a potential upside of 242.74%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than MorphoSys.
MorphoSys has a net margin of -226.79% compared to Gossamer Bio's net margin of -344.81%. MorphoSys' return on equity of -694.31% beat Gossamer Bio's return on equity.
Summary
Gossamer Bio beats MorphoSys on 11 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 10/3/2025 by MarketBeat.com Staff
Free GOSS Stock Alerts